Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.72 USD
-0.08 (-1.38%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $5.73 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TVTX 5.72 -0.08(-1.38%)
Will TVTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Other News for TVTX
FYBR, BCRX and SABR are among after hour movers
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
As more rare disease therapies launch, their prices are rising
What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International